← Compound index
COMPOUND RECORD / VLADONIX

VladonixВладоникс

An oral peptide mixture extracted from calf or pig thymus, studied in Russian immune-function reports.

Source linked

What the studies found

Observational study · 2013

Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency

Study of multiple preparations

IgG
1,202.27 → 1,445.20 mg/dLBefore and after the combination.p<0.01
CD4 cells
501.96 → 569.33 cells/µLp<0.01
IgM
126.56 → 132.46 mg/dLp<0.01

In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.

More reported outcomes
CD3 and CD8 cells
963.01 → 1,088.78 and 389.72 → 438.10 cells/µLp<0.01 and p<0.05, respectively
IgA, CD19 and CD4/CD8 ratio
No statistically significant changep>0.05
Author-defined overall outcome
105/150 good, 45/150 fairNo untreated group for this rating.
Study notes · methods, sources and limitations

Participants or model 150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.

Design The researchers compared immunoglobulins and lymphocyte markers before and after the 20-day regimen. Tables show paired assessment denominators of 150. The reference laboratory column is a population benchmark.

Important limitations

  • This was a before-and-after study of three products with no concurrent untreated group. Individual product effects and effects on infection risk remain uncertain. Program 33 reports 300 participants across two clinical series. The relationship between the two participant lists remains unverified.

Journal of Tropical Science and Technology. 2013;(2):78–84. · Publication record

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2022

Vladonix with recombinant IL-2 and interferon in COVID-19 outpatients

Moderate disease · duration
14 ± 1.9 vs 16 ± 2.2 daysAdjunct combination versus standard care, Table 1. The text gives 14.2 ± 2.2 vs 16.2 ± 2.4.
Moderate disease · post-COVID symptoms
3/12 vs 7/12Adjunct combination versus standard care. Recovery among these patients averaged 32.2 vs 36.2 days.
Worsening and reported adverse effects
No cases reportedNo group-level adverse-event table or systematic assessment method is provided.

In the 24-person moderate-disease comparison, Table 1 reports mean illness duration of 14 vs 16 days and post-COVID symptoms in 3 of 12 vs 7 of 12 patients with combination treatment versus standard care.

Study notes · methods, sources and limitations

Participants or model 48 PCR-confirmed outpatients aged 18–50 in Almaty and Semey, Kazakhstan. Mild and moderate disease each had 12 adjunct-treatment and 12 standard-care patients.

Design Each severity stratum had 12 patients per arm. Only the acute moderate combination included Vladonix. All patients received standard care.

Important limitations

  • Group assignment and masking are unclear. The combination prevents attribution to Vladonix alone. The illness-duration means differ slightly between Table 1 and the narrative. Post-COVID criteria and systematic adverse-event collection are not described.
  • The four small groups tested severity-specific combinations. They do not establish a separate Vladonix effect.

Terapevt. 2022(4):34–39 · Original journal article

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Comparison in people · 2006

Vladonix: clinical report on a tissue-derived preparation

CD4-positive cells
34.6% vs 30.8%Vladonix plus usual care versus usual care. Shared baseline 28.5%.Vladonix value marked p < 0.05 versus baseline.
CD3-positive cells
55.7% vs 51.9%Shared baseline 46.5%.Vladonix value marked p < 0.05 versus baseline.
CD4/CD8 ratio
1.4 vs 1.2Shared baseline 1.1.Vladonix value marked p < 0.05 versus baseline.

In the 76-person institute report, CD4-positive cells were 34.6% after adjunctive oral Vladonix and 30.8% after usual care, compared with a shared 28.5% baseline column.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

More reported outcomes
IgM, IgG, IgA and CD8-positive cells
No significant change markedTable 2 significance markers do not apply to these rows.
Study notes · methods, sources and limitations

Participants or model 76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.

Design 42 received adjunctive Vladonix and 34 conventional treatment alone. Peripheral-blood immunophenotyping used immunofluorescence. Immunoglobulins were measured by radial immunodiffusion.

Important limitations

  • Sex counts differ between prose and table. Immune biomarkers do not establish protection from radiation, fewer infections or improved cancer outcomes. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
  • The report provides a shared baseline column and no clear between-arm test. Its biomarker results do not establish fewer infections or better cancer outcomes.

Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date · Institute report — commercial reproduction

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Vladonix

Identity / background source ↗

Research background

Vladonix is a thymus-derived peptide preparation. Studies measured blood immune markers following radiation exposure and assessed symptoms in a multi-drug COVID-19 comparison.

Compound class
Tissue-derived peptide preparation
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

A 76-person report and a 48-person journal comparison. Acute Vladonix exposure was limited to the combination in the moderate COVID-19 subgroup.

Study methods

Small comparative institute report; allocation, blinding and outcome interpretation require caution

Independent replication

Independent replication not established in this collection

Source access

Original journal reports and reproduced institute data.

Safety evidence

Short-term reports do not establish long-term safety or equivalence to current products

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Observational study · 2013

Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency

In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.

Study notes and original source
2013Uncontrolled human reportFull text available

Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency

Vladoniks, Vezugen and Kristagen as named in the paper. Branded oral preparations.

Hoàng Văn Huấn, Phạm Khắc Linh, Nguyễn Như Nghĩa, and colleagues · Journal of Tropical Science and Technology. 2013;(2):78–84.

In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.

Results and tables

Reported findings and study design

The researchers compared immunoglobulins and lymphocyte markers before and after the 20-day regimen. Tables show paired assessment denominators of 150. The reference laboratory column is a population benchmark.

Population or model 150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.

Dose, route and schedule

Vladoniks, Vezugen and Kristagen were taken orally for 20 days. The paper lists 0.2 g of each preparation. It does not give purified peptide content or capsule frequency.

Protocol source ↗ · Original journal PDF, methods and Tables 1–6. Parent program report and Ministry of Defence project citation checked.

Results · Original journal PDF, methods and Tables 1–6. Parent program report and Ministry of Defence project citation checked.
MeasureResultComparison, timing and statistics
IgG1,202.27 → 1,445.20 mg/dLBefore and after the combination. · p<0.01
CD4 cells501.96 → 569.33 cells/µLp<0.01
IgM126.56 → 132.46 mg/dLp<0.01
CD3 and CD8 cells963.01 → 1,088.78 and 389.72 → 438.10 cells/µLp<0.01 and p<0.05, respectively
IgA, CD19 and CD4/CD8 ratioNo statistically significant changep>0.05
Author-defined overall outcome105/150 good, 45/150 fairNo untreated group for this rating.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.
Source reviewed
Original journal PDF, methods and Tables 1–6. Parent program report and Ministry of Defence project citation checked.
Study limitations
  • This was a before-and-after study of three products with no concurrent untreated group. Individual product effects and effects on infection risk remain uncertain.
  • Program 33 reports 300 participants across two clinical series. The relationship between the two participant lists remains unverified.

Reviewed 2026-11-14.

Read the source ↗

Comparison in people · 2022

Vladonix with recombinant IL-2 and interferon in COVID-19 outpatients

In the 24-person moderate-disease comparison, Table 1 reports mean illness duration of 14 vs 16 days and post-COVID symptoms in 3 of 12 vs 7 of 12 patients with combination treatment versus standard care.

Moderate disease · duration · 14 ± 1.9 vs 16 ± 2.2 days · Adjunct combination versus standard care, Table 1. The text gives 14.2 ± 2.2 vs 16.2 ± 2.4.

Study notes and original source
2022Human comparative studyFull text available

Vladonix with recombinant IL-2 and interferon in COVID-19 outpatients

Oral Vladonix A-6 thymus peptide complex, given with injectable recombinant IL-2 and intranasal interferon in the acute moderate branch. · Original journal article

N. Serikov, A. Zinatollayeva, Z. Karimova, N. K. Kudaibergenova, G. Zh. Abdrakhmanova, D. B. Kozubaeva, F. F. Yagofarov · Terapevt. 2022(4):34–39

In the 24-person moderate-disease comparison, Table 1 reports mean illness duration of 14 vs 16 days and post-COVID symptoms in 3 of 12 vs 7 of 12 patients with combination treatment versus standard care.

Results and tables

Reported findings and study design

Each severity stratum had 12 patients per arm. Only the acute moderate combination included Vladonix. All patients received standard care.

Population or model 48 PCR-confirmed outpatients aged 18–50 in Almaty and Semey, Kazakhstan. Mild and moderate disease each had 12 adjunct-treatment and 12 standard-care patients.

Dose, route and schedule

Moderate disease: Vladonix one capsule twice daily during illness with intranasal interferon alfa-2b and Roncoleukin (500,000 IU for 6–8 days). Acute mild disease received interferon and Roncoleukin without Vladonix. The post-COVID sections describe Vladonix for 10 or 30 days alongside Roncoleukin. Capsule peptide mass is unspecified.

Protocol source ↗ · Original journal PDF, methods and Table 1

Results · Original journal PDF, methods and Table 1
MeasureResultComparison, timing and statistics
Moderate disease · duration14 ± 1.9 vs 16 ± 2.2 daysAdjunct combination versus standard care, Table 1. The text gives 14.2 ± 2.2 vs 16.2 ± 2.4.
Moderate disease · post-COVID symptoms3/12 vs 7/12Adjunct combination versus standard care. Recovery among these patients averaged 32.2 vs 36.2 days.
Worsening and reported adverse effectsNo cases reportedNo group-level adverse-event table or systematic assessment method is provided.
Table 1 · illness duration and post-COVID cases
Table 1 · illness duration and post-COVID cases
GroupnIllness (days)Post-COVID casesRecovery (days)
Mild · interferon + IL-2128 ± 1.20—
Mild · usual care1210 ± 1.8128
Moderate · Vladonix + interferon + IL-21214 ± 1.9332.2
Moderate · usual care1216 ± 2.2736.2

Table 1 means are used for acute illness. For moderate post-COVID recovery the prose gives ±4.5 and ±4.1 days, respectively. The corresponding table uncertainty fields are malformed.

The four small groups tested severity-specific combinations. They do not establish a separate Vladonix effect.

Source for these results ↗ · Reviewed 2026-11-13

Population / setting
48 PCR-confirmed outpatients aged 18–50 in Almaty and Semey, Kazakhstan. Mild and moderate disease each had 12 adjunct-treatment and 12 standard-care patients.
Source reviewed
Original journal PDF, methods and Table 1
Study limitations
  • Group assignment and masking are unclear. The combination prevents attribution to Vladonix alone.
  • The illness-duration means differ slightly between Table 1 and the narrative. Post-COVID criteria and systematic adverse-event collection are not described.

Reviewed 2026-11-13.

Read the source ↗

Lab research · 2016

Vladonix, Endoluten and other peptides in cultured human blood cells

In cultured blood cells, Vladonix raised lysate IL-18 to 66.48 vs 39.06 pg/mL and lowered IL-1RA to 3,765 vs 5,228 pg/mL relative to saline.

Study notes and original source
2016In vitroFull text available

Vladonix, Endoluten and other peptides in cultured human blood cells

Six separately assayed peptide preparations supplied by the Khavinson laboratory. · Original journal article

M. V. Maksimenya, E. V. Fefelova, A. S. Bykova · Actual Problems of Humanities and Natural Sciences. 2016;12-3:97–100

Vladonix increased cell-lysate IL-18 to a median of 66.48 vs 39.06 pg/mL with saline and lowered IL-1RA to 3,765 vs 5,228 pg/mL. The study compared six preparations in cell culture.

Results and tables

Reported findings and study design

Saline-controlled cultures from 15 donors, 0.4 µg/mL for 24 hours. Lysate and supernatant were analyzed separately.

Population or model Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.

Dose, route and schedule

Cells were exposed to 0.4 µg/mL of each preparation or volume-matched saline for 24 hours at 37 °C. Cytokines were measured by ELISA in cell lysates and culture supernatant.

Protocol source ↗ · Original journal PDF, methods, Table 1 and culture-supernatant results

Results · Original journal PDF, methods, Table 1 and culture-supernatant results
MeasureResultComparison, timing and statistics
Vladonix · lysate IL-1866.48 vs 39.06 pg/mLMedian with Vladonix versus saline. · p < 0.001
Vladonix · lysate IL-1RA3,765 vs 5,228 pg/mLMedian with Vladonix versus saline. · p = 0.006
Endoluten · lysate IL-18 and IL-465.11 vs 39.06 and 28.40 vs 12.24 pg/mLEndoluten versus saline. · p = 0.02 and p < 0.001, respectively.
Crystagen and Cortexin · lysate IL-1875.10 and 60.02 vs 39.06 pg/mLEach preparation versus saline. Crystagen’s printed interval is inconsistent. · p = 0.004 and p = 0.04, respectively.
Vilon · lysate TNF-α and IL-1RA904.04 vs 598.05 and 4,056 vs 5,228 pg/mLVilon versus saline. · p = 0.045 and p = 0.02, respectively.
Epitalon · lysate IL-1RA4,346 vs 5,228 pg/mLEpitalon versus saline. · p = 0.047
Culture supernatantEndoluten IL-18 +33.46% and Vilon TNF-α +41.13%These were the only significant supernatant changes reported. Neither of the two Vladonix lysate findings was reported as significant in supernatant. · p = 0.02 and p = 0.035, respectively.
Table 1 · cell-lysate cytokines
Table 1 · cell-lysate cytokines
PreparationIL-18 (pg/mL)TNF-α (pg/mL)IL-4 (pg/mL)IL-1RA (pg/mL)
Saline39.06598.0512.245,228
Vladonix66.48*706.5417.623,765*
Endoluten65.11*429.0228.40*4,860
Crystagen75.10*505.2620.474,772
Vilon34.74904.04*9.964,056*
Epitalon30.62548.009.504,346*
Cortexin60.02*693.0015.044,921

Printed medians. Asterisks mark comparisons with saline at p < 0.05. The Crystagen IL-18 interquartile interval is printed as 66.46–70.62, which excludes the printed median.

The experiment measures cytokine concentrations after direct contact with cells. The clinical meaning and relevance to swallowing a capsule remain unknown.

Source for these results ↗ · Reviewed 2026-11-13

Population / setting
Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
Source reviewed
Original journal PDF, methods, Table 1 and culture-supernatant results
Study limitations
  • The volunteers donated blood and did not receive treatment. Culture concentrations cannot establish oral exposure or clinical effects.
  • The Crystagen IL-18 median lies outside its printed interquartile interval. Some narrative percentages differ from ratios calculated from tabulated medians.

Reviewed 2026-11-13.

Read the source ↗

Comparison in people · 2006

Vladonix: clinical report on a tissue-derived preparation

In the 76-person institute report, CD4-positive cells were 34.6% after adjunctive oral Vladonix and 30.8% after usual care, compared with a shared 28.5% baseline column.

Study notes and original source
2006Human comparative studyRussian-language source

Vladonix: clinical report on a tissue-derived preparation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date

In the 76-person institute report, CD4-positive cells were 34.6% after adjunctive oral Vladonix and 30.8% after usual care, compared with a shared 28.5% baseline column.

Results and tables

Reported findings and study design

42 received adjunctive Vladonix and 34 conventional treatment alone. Peripheral-blood immunophenotyping used immunofluorescence. Immunoglobulins were measured by radial immunodiffusion.

Population or model 76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.

Dose, route and schedule

One to three oral capsules, two to three times daily before meals for 15–20 days. The report lists 10 mg of thymus extract per capsule. Both arms received conventional care.

Protocol source ↗ · Russian institute-report reproductions, methods and Table 2

Results · Russian institute-report reproductions, methods and Table 2
MeasureResultComparison, timing and statistics
CD4-positive cells34.6% vs 30.8%Vladonix plus usual care versus usual care. Shared baseline 28.5%. · Vladonix value marked p < 0.05 versus baseline.
CD3-positive cells55.7% vs 51.9%Shared baseline 46.5%. · Vladonix value marked p < 0.05 versus baseline.
CD4/CD8 ratio1.4 vs 1.2Shared baseline 1.1. · Vladonix value marked p < 0.05 versus baseline.
IgM, IgG, IgA and CD8-positive cellsNo significant change markedTable 2 significance markers do not apply to these rows.

The report provides a shared baseline column and no clear between-arm test. Its biomarker results do not establish fewer infections or better cancer outcomes.

Source for these results ↗ · Reviewed 2026-11-13

Population / setting
76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.
Source reviewed
Russian institute-report reproductions, methods and Table 2
Study limitations
  • Sex counts differ between prose and table. Immune biomarkers do not establish protection from radiation, fewer infections or improved cancer outcomes.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Reviewed 2026-11-13.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗